Extending the criteria for acceptable organ donors: balancing the risks

• 1 Alfred Hospital, Melbourne, VIC
• 2 Monash University, Melbourne, VIC

---

• 1. Australia and New Zealand Organ Donation Registry. Organ waiting list. https://www.anzdata.org.au/anzod/reports/organ-waiting-list (viewed June 2019).
• 2. Rakhra SS, Opdam HI, Gladkis L, et al. Untapped potential in Australian hospitals for organ donation after circulatory death. Med J Aust 2017; 207: 294–301. https://www.mja.com.au/journal/2017/207/7/untapped-potential-australian-hospitals-organ-donation-after-circulatory-death
• 3. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta‐analysis. Am J Transplant 2011; 11: 1176–1187.
• 4. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis‐C infection in high infectious risk donors: systematic review and meta‐analysis. Am J Transplant 2011; 11: 1188–1200.
• 5. Waller KMJ, De La Mata NL, Kelly PJ, et al. Residual risk of infection with blood‐borne viruses in potential organ donors at increased risk of infection: systematic review and meta‐analysis. Med J Aust 2019; 211: 414–420.
• 6. Australia and New Zealand Dialysis and Transplant Registry. Mortality in end stage kidney disease. In: ANZDATA 41st annual report (2018). Adelaide: ANZDATA, 2018. https://www.anzdata.org.au/wp-content/uploads/2018/11/c03_mortality_2017v1.0_20181122.pdf (viewed June 2019).
• 7. Australia and New Zealand Liver Transplant Registry. 29th registry report 2017. Brisbane: ANZLTR, 2017. https://www3.anzltr.org/wp-content/uploads/Reports/29thReport.pdf (viewed June 2019).
• 8. Australia and New Zealand Cardiothoracic Organ Transplant Registry. 2018 report. http://www.anzcotr.org.au/pub/e0cc941a/PDFS/ANZCOTR2018_text.pdf (viewed 24 June 2019).
• 9. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA 2016; 316: 191–210.
• 10. Defresne F, Sokal E. Chronic hepatitis B in children: therapeutic challenges and perspectives. J Gastroenterol Hepatol 2017; 32: 368–371.
• 11. Liu SK, Seto WK, Lai CL, Yuen MF. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Rev Gastroenterol Hepatol 2016; 10: 697–707.
• 12. Vallet‐Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol 2011; 55: 474–482.
• 13. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 2005; 39: 58–63.
• 14. D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct‐acting antivirals: the endgame for hepatitis C? Curr Opin Virol 2017; 24: 31–37.
• 15. Goldberg DS, Abt PL, Reese PP; THINKER Trial Investigators. Transplanting HCV‐infected kidneys into uninfected recipients. N Engl J Med 2017; 377: 1105.
• 16. Schlendorf KH, Zalawadiya S, Shah AS, et al. Early outcomes using hepatitis C‐positive donors for cardiac transplantation in the era of effective direct‐acting anti‐viral therapies. J Heart Lung Transplant 2018; 37: 763–769.
• 17. Woolley AE, Singh SK, Goldberg HJ, et al; DONATE HCV Trial Team. Heart and lung transplants from HCV‐infected donors to uninfected recipients. N Engl J Med 2019; 380: 1606–1617.
• 18. Snell GI, Westall GP, Oto T. Donor risk prediction: how “extended” is safe? Curr Opin Organ Transplant 2013; 18: 507–512.
• 19. Eberlein M, Reed RM. Donor to recipient sizing in thoracic organ transplantation. World J Transplant 2016; 6: 155–164.